Skip to main content
Home
Issues
Issue Archive
Topics
Conference Correspondent
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
Issue Archive
Topics
Conference Correspondent
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
June 2023 Vol 16, No 1
Online Only
FDA Approvals
FDA Accelerated the Approval of Columvi for Selected Relapsed or Refractory Large B-Cell Lymphomas
Read More
Online Only
FDA Approvals
Lynparza FDA Approved, in Combination With Abiraterone and Prednisone (or Prednisolone), for Metastatic Castration-Resistant Prostate Cancer With BRCA Mutation
Read More
Online Only
FDA Approvals
Epkinly FDA Approved for Relapsed or Refractory Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma
Read More
Online Only
FDA Approvals
Polivy Received New Indication for First-Line Treatment of Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, and High-Grade B-Cell Lymphoma
Read More
Online Only
Original Research
,
Practice Management
,
Oncology
Trends in Utilization, Prices, and Spending for Oral Medications for Breast Cancer Treatment in the US Medicaid Population, 2008-2019
Fatimah Hussain Alyami, BPharm, MS, PhD; Jeff Jianfei Guo, BPharm, PhD
Read More
Results 1 - 5 of 5
